Alafair Biosciences Awarded Synthetic Implantable Products Agreement With Premier, Inc. for VersaWrap Hydrogel Sheet
Alafair Biosciences Awarded Synthetic Implantable Products Agreement With Premier, Inc. for VersaWrap Hydrogel Sheet
AUSTIN, Texas, July 2, 2024 /PRNewswire/ -- Alafair Biosciences, Inc., is revolutionizing soft tissue protection with innovative hydrogel medical devices, today announced that its flagship product, VersaWrap Hydrogel Sheet (VersaWrap), has been awarded a national group purchasing agreement with Premier, Inc. Effective July 1, 2024, the new agreement allows Premier members, at their discretion, to take advantage of special pricing and terms pre-negotiated by Premier for VersaWrap. VersaWrap is a class II medical device that allows tissues to glide and to remain untethered, thereby reducing reoperations and improving patient outcomes.
Alafair Biosciences, Inc.正在通过创新的水凝胶医疗器械革新软组织保护，今天宣布其旗舰产品VersaWrap水凝胶片（VersaWrap）已与Premier，Inc.获得了一个国家采购协议。从2024年7月1日起生效的新协议允许Premier成员自行决定是否利用Premier为VersaWrap预先谈判的特别定价和条款。VersaWrap是一种二类医疗器械，可以使组织滑动并保持脱节，从而减少再次手术，改善患者的预后。
"We are honored that Premier and its members reviewed our technology and awarded Alafair an agreement," stated John Joyoprayitno, President & CEO of Alafair Biosciences. "This agreement provides a meaningful opportunity for Alafair to broaden VersaWrap's reach to Premier members, clinicians, and, most importantly, patients nationwide. We anticipate this agreement to further fuel our momentum and enable us to continue delivering over 100% year-over-year growth."
“我们很荣幸Premier及其成员审查了我们的技术，并授予Alafair协议，” Alafair Biosciences的总裁兼首席执行官John Joyoprayitno表示。“该协议为Alafair提供了一个有意义的机会，将VersaWrap覆盖到Premier成员、临床医生、最重要的是全国患者。我们预计这个协议将进一步推动我们的势头，并使我们能够继续提供超过100%的年度增长。”
Premier is a leading healthcare improvement company, uniting an alliance of approximately 4,350 U.S. hospitals and 300,000 other providers to transform healthcare. With integrated data and analytics, collaboratives, supply chain solutions, consulting, and other services, Premier enables better care and outcomes at a lower cost.
Premier是一家领先的医疗保健改进公司，联合约4,350家美国医院和30万其他医疗服务提供商，以改变医疗业。通过整合数据和分析、协同作用、供应链解决方案、咨询和其他服务，Premier使患者获得更好的护理和预后，降低成本。
About Alafair Biosciences, Inc.
关于Alafair Biosciences，Inc。
Alafair is a privately held medical device company developing and marketing an innovative product portfolio based on its proprietary hydrogel technology. The mission of Alafair is to revolutionize surgical care with our versatile hydrogel technology, delivering unparalleled value to patients, surgeons, and healthcare facilities by enhancing soft tissue protection and by elevating patient outcomes. Alafair products are distributed through a dispersed network of independent distributors across the United States.
Alafair是一家私人持有的医疗器械公司，开发和营销基于其专有的水凝胶技术的创新产品组合。Alafair的使命是通过我们多用途的水凝胶技术革新外科护理，通过提高软组织保护和提升患者预后，为患者、外科医生和医疗保健机构提供无与伦比的价值。Alafair产品通过分散的美国独立经销商网络分销。
About VersaWrap Hydrogel Sheet
关于VersaWrap水凝胶片
VersaWrap is an FDA-cleared medical device implant (not tissue) comprising hyaluronic acid (HA) and alginate that provides a gelatinous encasement for peripheral nerves, tendons, and surrounding tissues such as ligaments and skeletal muscles. Our innovative technology allows tissues to glide and to remain untethered, thereby reducing reoperations and improving patient outcomes. VersaWrap offers unique surgical flexibility as the only tendon and nerve protector that can be delivered either as a sheet or as a flowable gel.
VersaWrap是经过FDA审批的医疗器械植入物（不是组织），包括透明质酸（HA）和海藻酸盐，为周围神经、肌腱以及周围组织如韧带和骨骼肌提供一种明胶封装。我们的创新技术可以使组织滑动并保持脱节，从而减少再次手术，改善患者预后。VersaWrap在提供唯一的腱和神经保护器方面具有独特的外科灵活性，可以作为片状或流动凝胶传递。
SOURCE Alafair Biosciences, Inc.
资料来源：Alafair Biosciences，Inc。